


Tirzepatide for Obesity Treatment and Diabetes Prevention

SURMOUNT-1

- Among patients with obesity and prediabetes, those who received tirzepatide experienced a mean body-weight reduction of up to 20%.
- This reduction was sustained over more than 3 years (176 weeks).
- Risk of progression to T2D was markedly lower than that with placebo.
- Almost 99% (752 of 762) of the participants who received tirzepatide remained.

SURMOUNT-1

Panel A: Percent change in body weight from baseline to week 176. **Panel B:** Percent change in body weight according to weeks since randomization. **Panel C:** Kaplan–Meier estimates of the percentage of participants in the safety analysis population who received a diagnosis of T2D during the course of the trial (during the 176-week treatment period and during the 17-week off-treatment period).



SURMOUNT-1

